Randomized double-blind study of efficacy and safety of topical 3% minoxidil solution combined with 0.25% finasteride solution versus 3% minoxidil solution in treatment of male androgenetic alopecia
Phase 3
Completed
- Conditions
- Androgenetic alopeciaMale pattern baldnessMale pattern alopecia
- Registration Number
- TCTR20160910002
- Lead Sponsor
- Division of Dermatology, Ramathibodi Hospital, Mahidol University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 40
Inclusion Criteria
1.Healthy male subject
2.Diagnosis of androgenic alopecia with class III and V Norwood-Hamilton classification
3.Agree to participate and signed informed consent form
Exclusion Criteria
1.History of hair transplant
2.Applying topical hair growth products within 2 weeks
3.Receiving light and laser treatment of the scalp within 3 months
4.Taking oral finasteride within 12 months
5.Taking dutasteride within 18 months
6.History of systemic illness
7.History of scalp diseases eg. seborrheic dermatitis, scalp infection.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy of topical 3% minoxidil solution combined with 0.25% finasteride solution 6 months Hair count and hair diameter
- Secondary Outcome Measures
Name Time Method Safety of topical 3% minoxidil solution combined with 0.25% finasteride solution 6 months Erythema, Scaliness, Inflammation and Systemic side effects